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The therapeutic role of creatine supplementation to treat musculoskeletal
toxicity in cancer

Abstract
Low muscle mass in individuals with cancer has a profound impact on quality of life and
independence, and is associated with greater treatment toxicity and poorer prognosis. Exercise
interventions are regularly being investigated as a means to ameliorate treatment-related adverse
effects, and nutrional/supplementation strategies to augment adaptations to exercise are highly
valuable. Creatine (Cr) is a naturally-occurring substance in the human body that plays a critical
role in energy provision during muscle contraction. Given the beneficial effects of Cr
supplementation on lean body mass, strength, and physical function in a variety of clinical
populations, there is therapeutic potential in individuals with cancer at heightened risk for muscle
loss. Here, we provide an overview of Cr physiology, summarize the evidence on the use of Cr
supplementation in various aging/clinical populations, explore mechanisms of action, and provide
perspectives on the potential therapeutic role of Cr in the exercise oncology setting.
Keywords: oncology, cachexia, body composition, muscle, bone, strength, resistance training,
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1.Introduction
Individuals with cancer are at a high risk of skeletal muscle wasting that may be exacerbated by
tumor-related factors and cancer therapies (certain hormone and chemotherapies in particular) [17]. An emerging body of literature supports the role of exercise as a means to ameliorate these
treatment-related declines and improve clinically relevant patient outcomes [7-10]. Indeed, the
existing evidence is that progressive resistance training (PRT) can improve physical function,
muscle strength and body composition in patients undergoing a variety of treatments [10-16].
Nevertheless, given the implications of low muscle mass on treatment toxicity and prognosis,
identifying strategies to enhance adaptations to exercise training in a cancer population are of both
clinical benefit and importance [17-20]. More recently, there has been an increasing appreciation
for the role of nutritional and dietary supplement interventions, both alone and with exercise, to
maintain or improve clinically relevant outcomes and augment training adaptations in cancer
patients [21-24].

Creatine (Cr) is one of the most extensively studied supplements, with research demonstrating its
efficacy to augment lean body mass (LBM) accretion, increase muscle strength, and improve
physical function in a variety of healthy and clinical populations [25]. More recently, Cr
supplementation has gained attention in the medical field as a result of the beneficial effects found
in numerous muscular and neurological diseases, such as McArdle disease, Duchenne dystrophy,
myasthenis gravis, amyotrophic lateral sclerosis, and Parkinson’s disease [17, 26, 27]. Given the
potent additive effects of Cr on muscle performance and LBM, it’s unsurprising that Cr is now
being considered as a therapeutic aid in some cancer contexts [28]. Nevertheless, supplementation
with Cr in a cancer context, particularly in human participants, is notably sparse. Paucity of
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research in this area may stem from lack of awareness of the potential role of Cr supplementation
in a cancer setting, misunderstanding of mechanisms of action, safety concerns from unfounded
media reports, or a combination of the above. Thus, the purpose of this narrative review is to
provide: (1) an overview of Cr physiology; (2) summarize studies investigating the therapeutic use
of Cr supplementation in cancer and other clinical populations; (3) provide perspectives on the
potential therapeutic role of Cr supplementation to treat cancer-related physical impairments, (4)
identify specific types of cancer groups that may benefit the most from supplementation and (5)
offer suggestions for future research.

2.Creatine metabolism
Cr is a naturally-occurring substance in the human body, synthesized endogenously in the kidneys,
pancreas and liver at a rate of ~1-2 g/day [29]. Additionally, approximately 1 gram of Cr can be
consumed by individuals with a diet high in meat and fish [30]. The majority of Cr (95%) is stored
in skeletal muscle (as free creatine or phosphocreatine), with the rest found in the brain and testes
[25]. Approximately 2 g/day of Cr is lost as creatinine in urine. Given that rates of excretion
typically match levels of endogenous production and intake, the most efficient way to increase
intramuscular Cr stores is through supplementation [30].

Cr is a component of the high-energy phosphate, phosphocreatine (PCr), which plays a critical role
in rapid energy provision during skeletal muscle contraction [21]. Re-phosphorylation of
adenosine diphosphate (ADP) to adenosine triphosphate (ATP) during and following exercise
(Figure 1) is reliant on the amount of PCr stored in the muscle (PCr + ADP ↔ Cr + ATP) [25].
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In addition to its role as a temporal energy buffer, PCr acts as a spatial energy buffer to shuttle
high-energy phosphates between mitochondria and cellular ATP utilization sites [31].

Fig 1. Phosphocreatine shuttle system. Creatine catalyzes reversible phosphorylation of creatine
to Phosphocreatine and ADP to ATP. (print in color)
It is hypothesized that Cr uptake by skeletal muscle is modulated by muscle activity [32]. As PCr
availability diminishes with intense exercise, ability to sustain exercise effort declines accordingly.
Further, an increase in availability of PCr may allow for accelerated resynthesis of ATP during
exercise [25, 33]. In this manner, PCr content in the muscle may be an important regulator of
exercise capacity. As a result, the ergogenic effects of Cr supplementation are likely an increase
in intramuscular PCr [32, 34], enhancing exercise capacity, and leading to an increase in training
quality and overall training volume [25, 33]. In other words, an increase in the body’s Cr stores
may allow for better recovery between sets of exercises or repeated efforts, allowing the individual
to perform more higher quality work and receive a better “dose” of exercise. When done
consistently, this can add up to potentially greater improvements in LBM and strength compared
to exercise alone.
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3.Creatine supplementation in healthy aging/clinical populations
This section is not intended to be an exhaustive review of the relevant literature examining Cr
supplementation in healthy aging/clinical populations. Rather, it is intended to outline the efficacy
of Cr supplementation using select studies representative of the broader body of literature in
improving relevant cancer-related outcomes (sarcopenia, loss of strength, bone health and physical
function) that are experienced in other populations. Studies were chosen based on research design
(randomised, double-blind, placebo-controlled), form of creatine used (creatine monohydrate),
population being studied (clinical patients and older adults), and dependent variable reported (body
composition and physical function). Indeed, more comprehensive reviews of Cr supplementation
are available in healthy aging [35-37], neurodegenerative [36, 38] and muscular disorders [39].

3.1Healthy aging
Aging is associated with an incremental loss in muscle mass, physical function, and independence.
Additionally, intramuscular stores of creatine are ~25% lower in older [40] and middle-aged adults
[41] than younger individuals. However, individuals with low intramuscular total Cr
concentrations show an enhanced ability to increase creatine content following Cr supplementation
[32]. Cr supplementation has been shown to increase muscle strength and function, enhance fatigue
resistance, and improve performance in activities of daily living irrespective of exercise training
in older populations [42, 43]. A summary of the studies discussed in this review examining Cr
supplementation in healthy aging/clinical populations are presented in Table 1.

Stout et al. [42] found significant increases in handgrip strength and physical working capacity
among elderly men and women supplementing with Cr for 14 days. The significant delay in the
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onset of neuromuscular fatigue, as measured by the physical working capacity (PWCFT) test, may
have been due to elevated muscle PCr content, which can decrease the reliance on anaerobic
glycolysis, reduce intramuscular lactate and ammonia accumulation, and therefore delay fatigue.
Short-term Cr supplementation has also been shown to improve upper and lower body muscular
strength. Gotshalk et al. [44] reported significant increases in bench press (4.11.4 kg) and leg
press (16.14.4 kg) strength, as well as significant improvements in lower body mean power and
timed sit-to-stand following 7 days of Cr supplementation in older men [45]. Supporting these
findings, Canete et al. [44] demonstrated a 12% improvement in timed sit-to-stand following 7
days of Cr supplementation in older women.

Cr supplementation in conjunction with PRT can result in greater adaptations in skeletal muscle
as compared with PRT alone. Multiple studies have shown greater improvements in strength when
Cr supplementation is combined with whole body PRT in older adults [49-51]. Results from a
meta-analysis undertaken by Devries and Phillips [37] indciated that Cr supplementation during
PRT enhanced the gain in LBM, strength, and functional performance over PRT alone in older
adults. Similarly, Brose and colleagues [46] reported significant increases in total body mass, fatfree mass, and isometric knee extension strength following 14 weeks of whole body resistance
training plus Cr supplementation. Furthermore, after a six-month randomized controlled trial,
researchers reported that Cr supplementation combined with PRT significantly increased
appendicular lean mass, maximal strength, and muscle function to a greater extent than PRT alone
in vulnerable older adults [47].
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Cr supplementation combined with PRT also has beneficial effects on bone health. In older men,
10 weeks of Cr supplementation (0.1g/kg) combined with a structured PRT completed three times
per week led to a significant reduction in bone resorption by 30% (assessed using the bone
biomarker NTx), compared to a non-significant increase of 13% in the placebo group [48]. These
results support previous findings from Chilibeck et al. [49], showing Cr supplementation (0.3g/kg
for 5 days, 0.07g/kg for 79 days) during 12 weeks of supervised PRT in healthy older males
significantly increased upper-limb bone mineral content (BMC) by 3.2%, compared to a nonsignificant decrease in the placebo group. Given that bone turnover is a relatively slow process
typically requiring 9 months to detect changes [50, 51], these findings are somewhat remarkable.

While several studies have indicated potential benefits from Cr supplementation on bone health,
others have found no effect. Lobo et al. [52] investigated the effects of long-term, low-dose Cr
supplementation (1g/day) without exercise for 52 weeks on bone health in postmenopausal women
and found that Cr had no greater effect on bone mineral density (BMD) or bone microarchitecture
compared to placebo. Additionally, Gualano et al. [47] showed no additional benefit of Cr
supplementation (20 g/day for 5 days + 5 g/day for 24 weeks) to PRT on lumbar spine, proximal
femur or whole body BMD, or serum bone markers in postmenopausal women. Further, Brose et
al. [50] found no effect from Cr supplementation (5g/day) on serum osteocalcin (indicator of bone
formation) in healthy older men following a 14-week PRT program. As it stands, results are mixed
in relation to Cr and bone health. Notably, studies employing higher volumes of resistance training
(i.e. greater number of sets per muscle group per week) combined with Cr supplememtation appear
to have a beneficial effect on LBM, muscle strength and physical function and bone health in older
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adults [37]. However, longer term studies (>12 months) with rigourous methodology utilising
higher training volume with Cr are warranted.

Table 1: Select studies examining the effects of Cr supplementation in healthy aging/clinical
populations
Authors

Patient/

(year)

subjects

Dosage

Protocol

Exercise

duration

program

Results

Adverse
Effects

Healthy
Aging
Brose et al

28 older

(2003) [46]

adults

Candow et

40 older men

al

5 g/day + 2
14 weeks
g of dextrose

0.10

10 weeks

g/kg/day

(2008)[48]

3 day/wk, 3

↑ Total body

None

x 10 total

mass; ↑ FFM; ↑

reported

body

Iso knee ext.

3 day/wk, 3

↑ Upper body

None

x 10 total

1RM **; ↔

reported

body

Lower body
1RM, ↓ 30%
bone
resorption, PLA
↑ 13% bone
resorption

Stout et al

15 older

20 g/day for

14 days of

(2007) [42]

adults

7 days then

Cr v PLA

10g/day

with 4-6

n/a

Cr ↑ GRIP and

None

PWCFT v PLA

reported

8

weeks
crossover
Gotshalk et

↑ 1RM, ↑ LBP,

None

al (2001)

↓

reported

[45]

STS, ↓ TG.

Chilibeck et

20 older men

29 older men

0.3g/kg/day

0.3g/kg/day

7 days

12 weeks

n/a

3 day/wk, 3

Cr ↑Upper limb

None
reported

al

for 5 days,

x 10 total

BMC. ↔Legs,

(2005)[49]

0.07

body

trunk or WB

g/kg/day for

BMC.

79 days
Gualano et

60 older

20 g/day for

al

women

(2014)[47]

24 weeks

2 day/wk, 3

↔ Lumbar

None

5 days + 5

x 8-12 total

spine, proximal

reported

g/day for 24

body

femur or WB

weeks
Lobo et al

109 post-

(2015)[52]

1 g/day

BMD
12 months

n/a

↔ Lumbar

None

menopausal,

spine, total hip

reported

osteopenic

or WB BMD

women
Gualano et

60 older

20 g/day for

al

women

(2014)[47]

24 weeks

2 day/wk, 3

↑ appendicular

None

5 days + 5

x 8-12 total

lean mass; ↔

reported

g/day for 24

body

fat mass.

weeks
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Clinical
Populations
Andrews et

20 patients

al(1998)
[53]

20g/day

5 days

n/a

↑ contractions

None

with chronic

before fatigue

reported

heart failure

at 75% MVC; ↓
lactate %
ammonia at
75% MVC

Louis et al

15 boys with

(2003)[54]

MD

3g/day

3 months

n/a

↑ MVC, TTE,

None

Cr and 3

BMD in

reported

months

ambulatory

PLA

patients.

separated

↓ urinary

by 2

excretion of

months

cross-linked N-

washout.

telopeptides of
Type I collagen
↓ urinary

None

Cr and 4

excretion of

reported

months

cross-linked N-

PLA

telopeptides of

separated

Type I

by 6 week

collagen**

Tarnopolsky

30 boys with

0.10

4 months

et al

MD

g/kg/day

(2004)[55]

n/a

washout.
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Sakkas et al

Patients with

20 g/day for

(2009)[56]

HIV infection

3 day/wk, 4

Greater ↑ LBM

None

5 days then

x 8 total

in Cr vs PLA.

reported

5g/day

body
↑ muscle

None

strength

reported

↑ handgrip

n/a

Walter et al

36 patients

10.6 g/day

(2000) [87]

with muscular

for 10 days

dystrophy

then 5 .3

12 weeks

8 weeks

n/a

g/day for 46
days
Tarnopolsky

30 boys with

0.10g/kg/da

4-month

et al (2004)

muscular

y,

supp, 6-

[58]

dystrophy

n/a

strength

week
wash-out,
4 month
PLA

BMC: Bone mineral content; BMD: Bone mineral density; BW: Bodyweight; Cr: creatine supplementation; g: gram; kg: kilogram; 1RM: 1
repetition maximum; FFM: Fat free mass; GRIP: maximal isometric grip strength; Iso: isometric; LBM: lean body mass; LBP: lower body power;
MD: muscular dystrophy; MVW: maximum voluntary contraction; PWCFT: physical working capacity at fatigue threshold; PLA: placebo group;
STS: sit-to-stand test; TG: tandem gait test; TTE: time to exhaustion; WB: whole body; n/a: not applicable; ↑: increase; ↓: decrease; ↔: no
change; **compared to Placebo
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3.2Clinical populations
Studies involving both human and animal models with various catabolic diseases have shown
evidence of increased LBM, bone density, muscle strength, and exercise performance following
Cr supplementation. HIV-infected persons often experience a loss of LBM [57], which has been
associated with accelerated disease progression and increased morbidity. A 2009 study by Sakkas
et al. [56] found that 14 weeks of Cr supplementation (20g/d for the first 5 days, followed by a
maintenance dose of 4.8 g/day), combined with progressive PRT for 12 weeks produced a greater
increase in LBM compared to the placebo + PRT group in patients with HIV infection.

Abnormalities of skeletal muscle in chronic heart failure patients include early onset of anaerobic
metabolism and a swift depletion of PCr [58, 59]. In addition to abnormalities of PCr during
exercise, patients with chronic heart failure have demonstrated a reduction in resting muscle Cr
content and a delay in resynthesis of PCr post-exercise [60, 61]. Andrews et al. [53] examined the
effects of Cr supplementation (20 g daily for 5 days) on repeated submaximal handgrip
contractions in elderly men with chronic heart failure. The authors found a significant increase in
the number of contractions performed before exhaustion at 75% maximum voluntary contraction
(MVC) workload following Cr supplementation. Additionally, ammonia and lactate
concentrations at the 75% MVC workload were significantly lower.

Muscular dystrophy is a genetic disease leading to muscle atrophy and bone loss. Researchers have
examined the effects of three months of Cr supplementation (3g/day) in boys with Duchenne and
Becker muscular dystrophy [54]. Participants in the Cr group who were able to walk during the
intervention saw a significant decrease in urinary excretion of cross-linked N-telopeptides of Type
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I collagen, an indicator of bone resorption, whereas participants in the placebo group experienced
a 6% increase. Cr supplementation also increased lumbar spine and whole-body BMD (assessed
via dual energy X-ray absorptiometry, DXA) by approximately 3.8% and 2%, respectively. No
effect was found in wheelchair-dependent individuals. Given the length of the normal bone
remodelling cycle, one could hypothesize an even greater increase in BMD following a longer
intervention [51].

Tarnopolsky et al. [55] investigated the effects of Cr supplementation (0.1g/kg) in young boys
with Duchenne muscular dystrophy for 4 months. Although no changes in whole body BMD or
BMC were observed, Cr supplementation did attenuate the increase in urinary excretion of crosslinked N-telopeptides of Type I collagen by 22% compared to placebo. In addition, Kley et al. [62]
conducted a meta-analysis on Cr and muscle disorders and concluded that Cr supplementation
given to patients with muscular dystrophies led to significant increases in LBM, as well as
maximum voluntary contraction, compared to placebo.

Differences in dosing, length of intervention, population being studied, and use of a PRT protocol
may explain some of the discrepancies among studies. Taken collectively, results from the
literature on Cr supplementation in healthy aging/clinical populations that demonstrate similar
muscle wasting characteristics often experienced by cancer patients (sarcopenia and cachexia)
indicate that Cr supplementation combined with PRT can result in superior improvements in
muscle mass, muscle strength and physical function. These findings are promising, though more
research is warranted to see if similar improvements are observed in individuals with cancer,
particularly those at a heightened risk of muscle wasting.
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4.Musculoskeletal dysfunction in cancer
Individuals with cancer are exposed to a variety of cancer-specific factors that result in decrements
in muscle mass and function, such as tumor-related factors, cancer therapies (in particular certain
hormone and chemotherapies), malnutrition, physical inactivity along with increasing age and
comorbidities [1-6]. To date, the primary focus of research around muscle toxicity has been
confined to cachexia. Importantly, sarcopenia is also a chief concern in this population, particularly
given the implications of decreased muscle mass and strength on the incidence and prevalence of
treatment toxicity and associations with poorer prognosis in lung cancer [63], colorectal cancer
[64], pancreatic cancer [65, 66] and renal cell carcinoma [1, 63, 67]. Sarcopenia and cachexia are
somewhat distinct in their etiology, though they can be interrelated in a cancer context whereby a
sarcopenic patient can become cachectic, or cachexia can exacerbate sarcopenic symptoms, further
depleting already low levels of muscle mass. Regardless, reductions in muscle mass and strength
are associated with profound decrements in quality of life and independence, greater toxicity from
treatment and all-cause mortality. The prevalence of muscle dysfunction varies based on the type
and stage of cancer, treatment received and methodology of measurement.

4.1Sarcopenia
Sarcopenia refers to the age-related loss of muscle mass and function that typically accelerates
with advancing age [3]. Characterized by changes in tissue quality, decreases in satellite cells,
denervation and/or atrophy of type II muscle fibers and an increase in myosteatosis (fat infiltration
in skeletal muscle); sarcopenia is associated with impairments in muscle strength, physical
function and may increase the risk of falls [68-70]. Sarcopenia may be of particular relevance in
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cancer, whereby many individuals are diagnosed at an older age, often presenting with sarcopenic
characteristics at diagnosis. Prevalence of sarcopenia in different types of cancer and stages of
disease has not been well defined in the oncology literature, likely compounded by lack of
universal diagnostic criteria [3]. Nevertheless, prevalence of sarcopenia in individuals with cancer
can range from 11-74% depending on the diagnostic criteria and methods of assessment [71-75].

4.2Cachexia
Cachexia is distinct from sarcopenia in that it is a more aggressive form of muscle wasting,
characterized by profound, unintentional weight loss (muscle and fat mass) that cannot be fully
ameliorated with nutritional interventions [5, 76, 77]. Indeed, development of cachexia further
depletes already low muscle mass, thereby exacerbating the development of sarcopenia. Criteria
for diagnosis of cachexia are a topic of ongoing discussion, though such criteria include weight
loss >5% in the past 6 months [76]. A discussion of the mechanisms of cachexia is beyond the
scope of this review, and for further information readers are referred to reviews by Tisdale [78]
and Aoyagi et al. [79] Briefly, this severe muscle wasting syndrome is thought to be a result of a
combination of factors, including systemic inflammation, tumor metabolism and tumor-mediated
effects, along with malnutrition and physical inactivity [76]. Cachexia is a major cause of
morbidity and mortality, and management of weight loss and cachectic symptoms are of high
clinical importance to minimize the impact of this syndrome [76, 80].

4.3Body composition
Cancer treatments are also associated with poor body composition, through loss of muscle mass
and/or increase in fat mass. Chemotherapy is regularly associated with increased adiposity during
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treatment, with some studies demonstrating significant increases in body fat percentage up to a
year following the cessation of treatment [81-86]. Accumulation of fat mass and/or loss of muscle
mass have been documented in prostate cancer patients undergoing androgen deprivation therapy
(ADT) [87-89]. Moreover, the use of corticosteroids to manage cancer and treatment side effects
is associated with weight gain and redistribution of body fat [90]. Indeed, Cushingoid features
(truncal obesity, dorsocervical and facial adiposity) can develop within the first two months of
glucocorticoid therapy [90].

Several mechanisms for the adverse changes in body composition with cancer treatments have
been proposed including lower levels of physical activity, development of menopause (in breast
cancer), and treatment-related metabolic perturbations [84]. Importantly, there is increasing
evidence that poor body composition and specifically, low muscle mass can increase severity of
treatment toxicities [18-20]. Moreover, impairments in muscle mass can predispose individuals to
a loss in physical function and the ability to perform activities of daily living, increase the risk of
falls and fractures, leading to a reduction in independence and quality of life (QoL), and an
increased risk of mortality [68-70, 91-94]. Clearly, identification of novel strategies to maintain or
improve muscle mass and strength is of high priority and clinical importance.

There is strong evidence suggesting Cr supplementation can promote the overexpression of genes
and proteins related to muscle hypertrophy [95, 96], as well as satellite cell activation [34]. Olsen
et al. [34] reported that in healthy humans, Cr supplementation in combination with PRT amplified
the increase in satellite cell number and myonuclei concentration in skeletal muscle fibers, thus
facilitating muscle growth and hypertrophy. Cr has also been shown to enhance expression of
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myogenin and other myogenic regulatory factors that regulate myosin heavy chain expression,
affecting the contractile protein content (actin and myosin) [97]. The growth-promoting effects of
Cr may be extremely useful in situations where anabolic activity is suppressed, such as muscle
wasting diseases, ageing populations, and cancer patients.

4.4Bone health
Cancer induced bone loss is indicated in the majority of cancers, with a variety of interrelated
factors from dietary and physical activity patterns, loss of muscle mass, cancer cells, cancer
therapies (particularly chemotherapy and hormone therapy) and metastatic disease [98, 99].
Indeed, reductions in bone health compounds muscle wasting by contributing to the loss of overall
lean body mass, poor physical functioning, and increased risk of fractures. Perturbations in the
tightly coupled process of osteoclast-mediated bone resorption and osteoblast-mediated bone
formation are common in a variety of cancers, particularly in a metastatic context, leading to a loss
of structural integrity and subsequent skeletal complications [98, 100, 101]. This greater rate of
bone turnover is likely due to an increase in osteoclast activity and bone resorption, coupled with
a decrease in osteoblast activity (bone formation); though the inverse can also be true in some
metastatic environments [98, 102-104]. Indeed, adverse changes in BMD coupled with a
deterioration in bone quality and microarchitecture increases fracture risk due to heightened bone
fragility.[98, 99, 103, 105, 106] Emerging evidence suggests Cr monohydrate may positively affect
bone physiology, possibly by increasing the activity of osteoblast-like cells involved in bone
formation [107, 108] and decreasing bone resorption.[48, 54, 55]
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5.Cr supplementation in cancer patients
The few studies examining the effects of Cr in cancer patients have been mixed, with some
showing no effect while others show some clinically meaningful benefit. A summary of these
studies can be found in Table 2. Jatoi et al. [28] examined Cr supplementation in 263 colorectal
cancer patients experiencing “anorexia/weight loss syndrome”. In this trial, incurable patients were
randomly assigned to either Cr (20g/day load x 5 days followed by 2 g/day) or placebo powder
with identical dosing. Body weight was assessed weekly for one month and thereafter monthly
while the patient remained on Cr or placebo. Appetite, QoL, and grip strength were also assessed.
The primary endpoint was the percentage of patients who gained 10% of their baseline weight
by 1 month. Out of 263 patients, only 3 gained 10% of their baseline weight over 1 month: two
in the Cr group, and one in the placebo group. No significant differences in any of the measured
variables were observed between the two groups. One possible explanation for lack of significant
findings is the absence of a training stimulus. It is hypothesized that Cr uptake by skeletal muscle
is modulated by muscle activity.[32] Muscle inactivity may contribute to a decrease in Cr uptake,
and therefore compromise the effect of Cr supplementation on body weight and strength.
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Table 2: Studies examining Cr supplementation in a cancer context.
Authors

Patients

Dosage

Protocol duration

(year)

Exercise

Results

program

Jatoi et al

362 cancer

20 g/day for 5

(2017)[28]

patients

days then

with

2g/day

9 months

n/a

Adverse
Effects

↔ body

None

weight

reported

↓ BF% Cr,

None
reported

weight loss
syndrome
Bourgeois et

Children

0.10 g/kg/day

2 x 16 weeks

n/a

al

with ALL

separated by 6

↑ BF% NH

(2008)[109]

undergoing

week wash-out

↔ BMD

chemother

period.

Cr

apy
Norman et al Colorectal

20g/day for 7

(2008)[110]

cancer
patients
undergoing

8 weeks

n/a

↑ body cell

None

days then

mass; ↑

reported

5g/day

cell
integrity

chemother
apy

19

Lonbro et al

30 Head

5g/day + 30g

(2012)[23]

and neck

Pro/day

12 weeks

3 day/wk, ↑ LBM

None

3 x 10

PROCR

reported

patients

total

group,ns↑

treated

body

PLA ↔

with

Muscle

radiotherap

Strength**

y

,↔
Physical
function**

ALL: acute lymphoblastic leukemia; BF%: body fat percentage; BMD: bone mineral density; Cr: creatine supplementation; g: gram; kg:
kilogram; LBM: lean body mass NH: natural history group; PLA: placebo; PROCR: Protein + creatine supplementation; n/a: not applicable; ↑:
increase; ↓: decrease; ↔: no change; **compared to Placebo.

Norman et al. [110] investigated the effects of 8 weeks of Cr supplementation on muscle function,
body composition and QoL in colorectal cancer patients. Patients were randomized to receive
either Cr monohydrate or a placebo. Patients in the Cr group received 20g/d for the first 7 days,
followed by 5g/d as a maintenance for the remainder of the study. Following 8 weeks of
supplementation, neither the Cr nor control group improved in assessments of body composition,
muscle function, or QoL. Importantly, this study had no exercise component across the 8 weeks.
Bourgeois and colleagues [109] investigated the effects of Cr supplementation with children on
maintenance chemotherapy for acute lymphoblastic leukemia for two periods of 16 weeks
separated by a 6-week “wash out” period. Participants in this study were also subject to
corticosteroid therapy as part of their cancer treatment. The authors found no effects of Cr
supplementation on body weight, lumbar spine BMD, whole body BMC or LBM. However, Cr
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supplementation was associated with a reduction in body fat in supplemented patients. This is an
important clinical finding considering those in the control group experienced a significant increase
in body fat across the duration of treatment. Lonbro et al.[23] examined feasibility and efficacy of
12 weeks of PRT in combination with protein and Cr supplementation (PROCR) in head and neck
cancer patients.[23] Patients were randomized into two groups: A PROCR group undergoing a
seven-day pre-trial creatine loading protocol (20g/day for 7 days) followed by 12 weeks of PRT
with Cr (5g/day) and protein (30g/day) supplementation and a placebo (PLA) group undergoing a
seven-day pre-trial placebo ingestion protocol followed by an identical PRT protocol with placebo
supplementation. LBM increased non-significantly (1.3 kg) in the PLA group and increased
significantly (2.6 kg) in the PROCR group. Though there were no statistically significant
differences between groups at 12 weeks, given the dramatic losses of LBM seen in this patient
population, the numerical two-fold (but not statistically signifcant) increase in LBM difference
between groups should be viewed as having potentially large clinical significance. Though
speculative, given that both groups consumed similar amounts of protein (as reported by mean
values across the intervention) throughout the study (despite supplementation in the PROCR
group), the Cr in the PROCR may have contributed to the additional LBM accrued in the PROCR
group.

6.The potential therapeutic role of Cr Supplementation to treat cancer-related physical
impairments.
The combination of cardiovascular, musculoskeletal, and neurological impairments experienced
by individuals with cancer, coupled with cancer-related fatigue, can result in deleterious effects on
physical function.[92] Indeed, individuals with cancer can often present with low physical function
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status at the onset of treatment, or experience severe deterioration over the course of
treatment.[111-113] Reductions in performance measures such as gait speed, stair climbing ability
and timed up and go are regularly seen amongst cancer patients and survivors, particularly when
compared to apparently healthy controls.[114-116] Undoubtedly, these decrements in physical
function are inextricably linked to the decline of force-generating capabilities of skeletal muscle.

Impairments in muscle strength and an increase in fatigability are regularly reported in patients
following cancer treatment.[115] Burden et al.[117] found that in a sample of 87 early-stage
colorectal patients, about half (54%) had a handgrip strength <85% below the reference
range.[118] Advanced prostate cancer patients undergoing ADT have shown 29% lower handgrip
strength compared to healthy controls. Further, breast cancer survivors have displayed lower
muscle strength (20-30%) in multiple upper body exercises compared with healthy
individuals.[119] The clinical implications of these reductions in muscle strength and physical
function in individuals with cancer are of critical importance, as those with lower levels of physical
function are more likely to experience premature mortality than those with higher physical
function.[92-94] Galvao et al.[120] proposed a theoretical model of the role of PRT to improve
musculoskeletal fitness, resulting in an increase in physical reserve capacity in men treated with
ADT. Here, we propose that Cr supplementation in addition to PRT may provide even more
improvements in musculoskeletal fitness, results in a greater increase in physical reserve capacity
(Figure 2). The changes have important implications in preserving physical function with age, and
reducing the risk of falls and fractures amongst individuals with cancer.
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Figure 2. Theoretical model of the role of RT and Cr to attenuate musculoskeletal fitness decline
in individuals with cancer.(Modified from Galvao et al. Prostate Cancer Prostatic Dis 2008)
Certain cancer therapies can exacerbate declines in muscle mass and strength, leading to an
accelerated decline in physical function toward a “disability” condition, or lack of independence.
It has been proposed that PRT may delay this decline through increases in muscle mass, strength
and functional ability. Here, we suggest that Cr supplementation in addition to PRT may lead to
further improvements, potentially delaying this decline even longer. (print in color)
To date, only one trial has investigated the effects of Cr supplementation on physical function in
individuals with cancer. The results of the DAHANCA 25A trial [23] in head and neck cancer
patients that received radiotherapy, demonstrated that PRT increased muscle strength and
functional performance with no additive effect of protein and Cr supplementation on physical
function. However, the authors urged caution in interpretation of the results due to the low number
of participants, minimal supervision during the training sessions, and adherence to the supplement
only being reported using a questionnaire.
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While the physiological mechanisms linking Cr supplementation to an increase in exercise
performance are yet to be fully elucidated, one possibility is an increase in PCr content in Type II
muscle fibers. PCr content is 5-15% higher in Type II than Type I fibers.[121, 122] Additionally,
the rate of PCr degradation is faster in Type II than Type I fibers during high-intensity, short
duration activities.[121] Conversely, Type I fibers resynthesise PCr at a faster rate than Type II
fibers during recovery periods. After Cr supplementation, both fiber types increase total and PCr
content, with a trend toward a larger increase in Type II fibers.[123] Type II muscle fibers are
associated with higher anaerobic ATP turnover rate and peak power output during exercise.
Evidence suggests that fatigue during intense muscle contraction may be attributable to the
utilization of PCr, specifically in Type II muscle fibers.[124] Therefore, any mechanism capable
of increasing intramuscular Cr stores may help to prevent PCr depletion, and delay fatigue, during
intense exercise.

Earlier work by Harris et al.[32] showed increases in skeletal muscle Cr content by 20-50%
following Cr supplementation, with 20% of the increase in Cr accounted for by increases in PCr.
Although it is unclear whether or not cancer patients experience a significant decrease in PCr
stores, there is evidence in clinical populations with muscle atrophy demonstrating depletion of
intramuscular stores of PCr in Type II muscle fibers.[125] Therefore, while further research is
needed in individuals with cancer, results from other clinical populations and muscle wasting
diseases suggest it is plausible that Cr supplementation may have beneficial effects on muscle
function and performance in this patient population.
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7.Which cancer groups are most likely to benefit from Cr supplementation
The heterogeneity of cancer type, treatments, definitions of sarcopenia and cachexia, along with
methods of assessment, makes it difficult to accurately define the prevalence of muscle wasting in
cancer. Pamoukdjian et al.[72] indicated that patients with local oesophageal cancer and small-cell
lung cancer represented the highest prevalence of pre-therapeutic sarcopenia, with respective
values of 75% and 79.2%. In a study of 390 cancer patients, Sun et al.[126] found the highest
prevalence of cachexia in pancreatic cancer (98.9%), gastric cancer (76.5%) and esophageal cancer
(52.9%). Geriatric cancer patients are particularly vulnerable, given the already low muscle mass
in this population. Indeed, Prado et al.[127] found 68% of cancer patients with sarcopenia were
over the age of 65. Additionally, certain cancer treatments can result in muscle loss and
dysfunction, such as ADT for prostate cancer.[88]

Certainly, given the results of studies in healthy aging and other clinical populations, any
individual with cancer engaging in resistance training stands to benefit from Cr supplementation.
Nevertheless, there may be subsets of cancer types, or treatments that may see greater benefit with
Cr supplementation. Indeed, the highest prevalence of weight loss and cachexia has been observed
in head and neck, pancreatic, lung, colorectal and gastric cancer.[3, 127] Older adults may be
particularly vulnerable to muscle loss and could potentially benefit from Cr supplementation.
Additionally, those undergoing certain treatments such ADT for prostate cancer are at a higher
risk for muscle loss indicating the potential utility of Cr supplementation.
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8.Safety considerations
Despite the expansive research supporting Cr as a safe and highly effective nutritional supplement
in healthy aging and individuals with neurological/muscle disorders,[25, 33] it remains largely
misunderstood, with unsubstantiated claims of side effects such as kidney and liver damage and
dehydration. Contrary to these claims, Cr supplementation has not been associated with any signs
of renal impairment.[25, 33, 128] Indeed, the safety of Cr supplementation on kidney function as
measured by glomerular filtration rate has been demonstrated in a variety of apparently healthy
and clinical populations.[129-132] In fact, Cr supplementation is being considered as a means to
improve musculoskeletal and neurological functioning in patients with chronic kidney disease.[27]
Long-term Cr supplementation has been investigated in other clinical populations such as
Parkinson’s disease and Huntington’s disease, in studies ranging from 2-5 years, and doses up to
10g/day, with no adverse effects of supplementation or impact on renal dysfunction reported. [133135]

Further, studies of Cr supplementation have reported no adverse effects on hydration status or
muscle cramps. Researchers have conducted a meta-analysis and reported no evidence of altered
hydration status or thermoregulation following Cr supplementation.[136] Additionally,
Greenwood et al [137] found no increase in dehydration, cramping, and/or muscle injury rates
among college football players following long-term (3 years) Cr supplementation. Cr is one of the
most rigorously studied supplements to date, with hundreds of studies demonstrating safety,
tolerability, and wide ranging health and performance benefits.[25, 33] Moreover, there is no
compelling evidence that short- or long-term Cr supplementation has any detrimental effects on
kidney function, gastrointestinal distress, muscle dysfunction or hydration status.[25, 33, 129-132]
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It should be noted however, that given the paucity of research examining Cr supplementation in
patients with cancer, studies examining the safety and tolerability of Cr in a cancer context, in
particular interactions with treatments such as radiation therapy, chemotherapy, steroid therapy
and immunotherapy, are necessary.

9.Conclusions and future directions
Given the beneficial effects of Cr supplementation on muscle mass, strength, BMD and physical
function in a variety of clinical populations, the therapeutic potential for application in cancer is
substantial. Indeed, randomized controlled trials are beginning to emerge, investigating the effects
of Cr supplementation to attenuate cancer-related weight loss.[28] Nevertheless, application in
various cancer contexts is still largely theoretical, with research in this area remaining sparse.
Consequently, additional RCT’s are needed in this area to fully understand the impact of
supplementation on clinically-meaningful outcomes in individuals with cancer, in particular those
at a higher risk of muscle wasting, such as head and neck, pancreatic, and gastrointestinal cancers.

The majority of studies in this area have examined Cr supplementation in isolation on clinical
outcomes in individuals with cancer. Importantly, the beneficial effects of Cr supplementation are
more likely a result of an increase in intramuscular Cr stores allowing an individual to get a greater
“dose” of exercise, which can accumulate over time, leading to greater adaptations to exercise
training (such as muscle mass, strength and physical function), than of the supplement alone.
Accordingly, we recommend that future studies examine the effects of Cr supplementation in
conjunction with resistance exercise on important clinical outcomes in individuals with cancer at
a heightened risk of muscle loss (as mentioned above), such as muscle mass, strength and physical
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function. Additionally, experiments in vitro or with animals are warranted to determine the
mechanisms of effects of Cr to treat skeletal muscle toxicity in individuals with cancer.
Collectively, further research in this area will allow for a greater understanding of the therapeutic
effects of Cr supplementation in this patient population.
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